Drug Profile
RGX 314
Alternative Names: ABBV-RGX-314; RGX-314Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator REGENXBIO
- Developer AbbVie; REGENXBIO
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Wet age-related macular degeneration
- Phase II Diabetic retinopathy
- Preclinical Retinal disorders
Most Recent Events
- 28 Mar 2024 REGENXBIO announces intention to submit Biologics license application (BLA) to the US FDA for Wet age-related macular degeneration in late 2025 through the first half of 2026
- 28 Mar 2024 REGENXBIO announces intention to submit regulatory application to the EMA for Wet age-related macular degeneration in late 2025 through the first half of 2026
- 16 Jan 2024 Updated efficacy and adverse events data from the phase II AAVIATE trial in Wet age-related macular degeneration released by REGENXBIO